Focus: Cancer Center Featured Story 2

Filters close
access_time Embargo lifts in 2 days
This news release is embargoed until 28-Feb-2024 11:00 AM EST Released to reporters: 27-Feb-2024 11:05 AM EST

A reporter's PressPass is required to access this story until the embargo expires on 28-Feb-2024 11:00 AM EST The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Newswise: Roswell Park Study First to Show Two-Drug Combination Selectively Targets p53-Mutant Cancers
Released: 26-Feb-2024 11:30 AM EST
Roswell Park Study First to Show Two-Drug Combination Selectively Targets p53-Mutant Cancers
Roswell Park Comprehensive Cancer Center

A preclinical study led by a team of researchers at Roswell Park Comprehensive Cancer Center highlights the potential of a novel two-drug treatment strategy targeting p53-mutant cancers.

Released: 26-Feb-2024 9:10 AM EST
Moffitt Study Highlights Urgent Need to Address Impact of Extreme Weather Events on Cancer Survivorship
Moffitt Cancer Center

In a mini-review published in Cancer Epidemiology, Biomarkers & Prevention, a journal from the American Association for Cancer Research, Moffitt Cancer Center researchers shed light on the significant gaps in understanding and addressing the effects of hurricanes and extreme weather events on biological, psychosocial and clinical outcomes among cancer survivors.

Released: 26-Feb-2024 9:00 AM EST
Dana-Farber and Gustave Roussy to hold third Transatlantic Exchange: Annual scientific conference dedicated to advancing Oncology research and practice
Dana-Farber Cancer Institute

Dana-Farber Cancer Institute (Boston, MA, USA) and Gustave Roussy (Grand Paris, Villejuif, France) have announced that the third Transatlantic Exchange in Oncology Conference will address: Liquid Biopsy as an Emerging Approach in Precision Cancer Medicine.The meeting, supported by L’Institut Servier, will be held in-person (witha virtual attendance option) on April 12, 2024, at the Revere Hotel Boston Common and livestreamed virtually on Medscape’s platform.

Released: 23-Feb-2024 2:45 PM EST
MD Anderson acquires inducible switch technologies for cell therapy
University of Texas MD Anderson Cancer Center

MD Anderson has acquired certain assets from Bellicum Pharmaceuticals, Inc. related to the CaspaCIDE switch and GoCAR platforms. As a result, MD Anderson may incorporate these technologies into its own cell therapy programs as well as make them available for licensing to interested parties.

Newswise: Researchers Look at Ways to Target Early Breast Cancer Progression
Released: 22-Feb-2024 3:05 PM EST
Researchers Look at Ways to Target Early Breast Cancer Progression
University of Kansas Cancer Center

A researcher at The University of Kansas Cancer Center has received a $930,000 grant from the U.S. Department of Defense to study a new targeted therapy option for people diagnosed with ductal carcinoma in situ (DCIS).

21-Feb-2024 12:05 PM EST
Kidney cancer treatments and tumor biology can activate different immune-modifying processes in patients
Dana-Farber Cancer Institute

The findings out of Dana-Farber Cancer Institute highlight that the mechanisms of immune modulation are different in patients treated with immunotherapy and anti-angiogenic combinations. The results also point to the role of tumor biology in the diversity and actions of tumor-infiltrating immune cells brought into action by these treatments. The findings might be important for predicting or understanding treatment outcomes in advanced kidney cancer.

Released: 22-Feb-2024 8:30 AM EST
Advocating for Equitable Cancer Care: A Call to Establish Comprehensive Survivorship Programming and Enhance Genetic Testing Discussions
National Comprehensive Cancer Network® (NCCN®)

Two new measurements have been added to the Health Equity Report Card (HERC)—a tool for improving the quality and equity of cancer care. This expansion is part of ongoing efforts to address the impact of structural and interpersonal racism as a cause of disparities in cancer outcomes in the United States.

Released: 21-Feb-2024 4:00 PM EST
MD Anderson researchers receive over $25.5 million in CPRIT funding
University of Texas MD Anderson Cancer Center

The University of Texas MD Anderson Cancer Center today was awarded 16 grants totaling over $25.5 million from the Cancer Prevention and Research Institute of Texas (CPRIT) in support of cancer screening, early detection and prevention programs, faculty recruitment, and groundbreaking cancer research across all areas of the institution.

   
Newswise: TB vaccine shrinks liver cancer tumors in mice
Released: 21-Feb-2024 2:05 PM EST
TB vaccine shrinks liver cancer tumors in mice
UC Davis Health

Could the TB vaccine be a new immunotherapy for liver cancer? A UC Davis Health study found that the century-old vaccine reduced tumors and extended survival for mice with liver cancer.

Released: 21-Feb-2024 12:00 PM EST
MD Anderson Research Highlights for February 21, 2024
University of Texas MD Anderson Cancer Center

The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back. Recent developments at MD Anderson offer insights into drug-drug interactions for patients with acute myeloid leukemia (AML) and myelodysplastic syndromes; patient-derived xenograft models as a viable translational research tool in early-phase clinical trials; a novel gene expression signature to stratify patients with bladder cancer; a potential therapeutic target to overcome treatment resistance in multiple myeloma; a role for mutant p53 in protecting against ferroptosis in triple-negative breast cancer; and diet modifications to improve treatment outcomes in FLT3-mutated AML.

   
Released: 19-Feb-2024 3:05 PM EST
Moffitt Plays Pivotal Role in FDA Approval of Tumor-Infiltrating Lymphocyte Therapy for Advanced Melanoma
Moffitt Cancer Center

A first-of-its-kind cellular immunotherapy pioneered at Moffitt Cancer Center has received approval from the Food and Drug Administration and is now available for patients with advanced melanoma. Lifileucel is the first tumor-infiltrating lymphocyte therapy, or TIL, approved for solid tumors.

Newswise: Rutgers Women’s Basketball Partners with RWJBarnabas Health/Rutgers Cancer Institute and Kay Yow Cancer Fund to Establish the Rutgers Women’s Basketball Cancer Support Game Plan
Released: 19-Feb-2024 12:05 PM EST
Rutgers Women’s Basketball Partners with RWJBarnabas Health/Rutgers Cancer Institute and Kay Yow Cancer Fund to Establish the Rutgers Women’s Basketball Cancer Support Game Plan
Rutgers Cancer Institute of New Jersey

The Scarlet Knights presented a $50,000 check from the Kay Yow Cancer Fund to RWJBarnabas Health and Rutgers Cancer Institute of New Jersey to establish the Rutgers Women’s Basketball Cancer Support Game Plan, which will provide funding assistance for underserved female cancer patients across the State of New Jersey.

Newswise: Spurring Action Against Cervical Cancer
Released: 16-Feb-2024 1:05 PM EST
Spurring Action Against Cervical Cancer
University of New Mexico Comprehensive Cancer Center

Prajakta Adsul, MBBS, PhD, MPH, from UNM Cancer Center attended the White House Cervical Cancer Forum focused on education, prevention, early detection and treatment. The Forum was held in late January.

Released: 16-Feb-2024 10:05 AM EST
Moffitt Study Finds Neoadjuvant Chemotherapy Significantly Improves Outcomes for Penile Squamous Cell Carcinoma Patients
Moffitt Cancer Center

In a new article published in the Journal of the National Cancer Institute, Moffitt Cancer Center researchers share data on the efficacy and safety of neoadjuvant chemotherapy for locally advanced penile squamous cell carcinoma, addressing a critical gap in evidence regarding treatment options for this rare and aggressive cancer.

Released: 15-Feb-2024 11:05 AM EST
Do sugar-free candy and gum give you gas? Researchers think they know why
UC Davis Health

Scientists at the UC Davis School of Medicine may have figured out why some people have trouble digesting sorbitol, a sugar alcohol used in sugar-free gum, mints, candy and other products.

12-Feb-2024 5:05 PM EST
Immunotherapy before surgery leads to promising long-term survival in sarcoma patients
University of Texas MD Anderson Cancer Center

Patients with soft-tissue sarcoma treated with neoadjuvant, or pre-surgical, immunotherapy had very little residual tumor at the time of surgery and promising long-term survival, according to Phase II trial results published today in Nature Cancer by researchers at The University of Texas MD Anderson Cancer Center

Newswise: Biomarker-directed combination effective in immunotherapy-resistant lung cancer
12-Feb-2024 5:00 PM EST
Biomarker-directed combination effective in immunotherapy-resistant lung cancer
University of Texas MD Anderson Cancer Center

A specific combination of targeted therapy and immunotherapy may better help patients with non-small cell lung cancer (NSCLC) overcome inherent immune resistance and reinvigorate anti-tumor activity, according to a new study led by a researcher from The University of Texas MD Anderson Cancer Center.

Released: 9-Feb-2024 10:05 AM EST
Moffitt Develops First Individualized Predictive Model for Multiple Myeloma Treatment
Moffitt Cancer Center

In a new article published in the Journal of Clinical Oncology, Moffitt Cancer Center researchers in collaboration with Sylvester Comprehensive Cancer Center and groups around the world share results from a novel model that can provide tailored predictions of how individual patients respond to different therapies.

Released: 8-Feb-2024 3:00 PM EST
Novel Treatment Regimen for FLT3-Mutated Acute Myeloid Leukemia Shows Promise in Roswell Park-Led Study
Roswell Park Comprehensive Cancer Center

Up to 30% of patients newly diagnosed with acute myeloid leukemia (AML) have an FLT3 gene mutation, which is associated with a high risk of relapse and a very poor prognosis.

Released: 7-Feb-2024 5:00 PM EST
MD Anderson and C-Biomex sign collaborative research agreement to co-develop CBT-001 radioligand therapy
University of Texas MD Anderson Cancer Center

MD Anderso and C-Biomex today announced a strategic collaboration to co-develop CBT-001, a radioligand targeting the CA9 cancer biomarker.

Released: 7-Feb-2024 12:00 PM EST
MD Anderson Research Highlights for February 7, 2024
University of Texas MD Anderson Cancer Center

The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention.

   
Newswise: New Resource for Selecting Best Treatment Path for Young Children with Cancerous Tumors Published by NCCN
Released: 7-Feb-2024 9:00 AM EST
New Resource for Selecting Best Treatment Path for Young Children with Cancerous Tumors Published by NCCN
National Comprehensive Cancer Network® (NCCN®)

New NCCN Guidelines for Neuroblastoma address the importance and impact of risk stratification for treating one of the more common types of pediatric solid tumors; includes vanguard treatment recommendations involving multimodality treatment for high-risk disease.

Newswise: Immune networks in tumors prime responses to a personalized immunotherapy
Released: 6-Feb-2024 11:05 AM EST
Immune networks in tumors prime responses to a personalized immunotherapy
Ludwig Cancer Research

Through an analysis of tumor samples collected over time from patients with advanced melanoma, a Ludwig Cancer Research study has identified a set of preexisting conditions in tumors that predict whether such patients are likely to respond to a personalized immunotherapy known as adoptive T cell therapy (ACT) using tumor-infiltrating lymphocytes (TIL).

Released: 6-Feb-2024 10:05 AM EST
Moffitt Study Suggests Improvements Needed for Patient-Reported Outcome Data in Genitourinary Cancer Clinical Studies
Moffitt Cancer Center

In a recent study published in eClinicalMedicine, part of The Lancet Discovery Science, Moffitt Cancer Center researchers demonstrate that there is a significant unmet need for improved analyses and reporting of patient-reported outcomes in genitourinary cancer clinical trials.

Newswise: $1.1M Grant Supports Research in Breast Cancer Survivorship among Black Women
Released: 6-Feb-2024 8:05 AM EST
$1.1M Grant Supports Research in Breast Cancer Survivorship among Black Women
Rutgers Cancer Institute of New Jersey

Bo (Bonnie) Qin, PhD, researcher and cancer epidemiologist in the Section of Cancer Epidemiology and Health Outcomes at Rutgers Cancer Institute of New Jersey, has received $1.1M from the American Cancer Society to support her research on the impact of lifestyle patterns, social determinants of health, and inflammatory mechanisms on breast cancer survivorship among Black women.

Newswise: Awards totaling $2.6 Million Support Exploration of Therapeutic Strategy for Adult and Pediatric T-cell Acute Lymphoblastic Leukemia
Released: 6-Feb-2024 8:05 AM EST
Awards totaling $2.6 Million Support Exploration of Therapeutic Strategy for Adult and Pediatric T-cell Acute Lymphoblastic Leukemia
Rutgers Cancer Institute of New Jersey

Daniel Herranz Benito, PhD, PharmD, resident researcher at Rutgers Cancer Institute of New Jersey, the state’s leading cancer program and only NCI-designated Comprehensive Cancer Center together with RWJBarnabas Health, and associate professor of pharmacology and pediatrics at Rutgers Robert Wood Johnson Medical School, has received a total of $2.6M to support his research on acute lymphoblastic leukemia (ALL), an aggressive type of leukemia that affects both children and adults.

Released: 5-Feb-2024 5:05 PM EST
New AI technology is helping UC Davis physicians quickly identify stroke
UC Davis Health

UC Davis Health has adopted a new technology platform, Viz.ai, to help quickly identify patients suspected of having a stroke. The hospital is the first in the Sacramento region to use the platform.

Newswise: Director of Oncology Services Northern Region Named to New Jersey’s Only NCI-designated Comprehensive Cancer Center
Released: 5-Feb-2024 9:30 AM EST
Director of Oncology Services Northern Region Named to New Jersey’s Only NCI-designated Comprehensive Cancer Center
Rutgers Cancer Institute of New Jersey

George Raptis, MD, MBA, begins role at Rutgers Cancer Institute of New Jersey and RWJBarnabas Health as director of Oncology Services for the Northern Region of New Jersey.

Newswise:Video Embedded memorial-sloan-kettering-launches-bilingual-campaign-promoting-screenings-in-the-hispanic-community
VIDEO
2-Feb-2024 5:00 PM EST
Memorial Sloan Kettering Cancer Center Launches Bilingual Campaign Promoting Screenings in the Hispanic Community
Memorial Sloan Kettering Cancer Center

Today, Memorial Sloan Kettering Cancer Center (MSK), in collaboration with Miami-based creative agency Alma, launched a bilingual public service campaign to promote the importance of routine cancer screenings.

Newswise: adobestock_181431116.jpg
Released: 2-Feb-2024 1:55 PM EST
Roswell Park Study Defines Mechanisms Underlying Promising Precision Therapy for Pancreatic Cancer
Roswell Park Comprehensive Cancer Center

A research study led by a multidisciplinary team of scientists at Roswell Park Comprehensive Cancer Center details evidence on the therapeutic efficacy of a compound that targets a key genetic feature of pancreatic cancer.

Released: 2-Feb-2024 1:40 PM EST
Simple Blood Protein Tests Predict Which Lymphoma Patients Are Most Likely to Have Poor CAR T Outcomes
Roswell Park Comprehensive Cancer Center

As new cancer treatments become available, some of the most important ongoing research must look at ways to optimize those new approaches so that more patients can benefit from groundbreaking therapies.

Released: 2-Feb-2024 1:25 PM EST
FL118, Drug Candidate Discovered at Roswell Park, Granted FDA Orphan Drug Status for Pancreatic Cancer
Roswell Park Comprehensive Cancer Center

The U.S. Food and Drug Administration (FDA) has awarded Orphan Drug Designation to Canget BioTekpharma LLC for FL118, a drug candidate developed at Roswell Park Comprehensive Cancer Center, as a possible treatment for pancreatic cancer.

Newswise: For World Cancer Day, Alliance for Cancer Care Equity Advocates to ‘Close the Care Gap’ as Observance is Honored with Congressional Resolution
Released: 1-Feb-2024 2:15 PM EST
For World Cancer Day, Alliance for Cancer Care Equity Advocates to ‘Close the Care Gap’ as Observance is Honored with Congressional Resolution
National Comprehensive Cancer Network® (NCCN®)

For World Cancer Day, February 4th, NCCN, ACS CAN, and NMQF are announcing three key areas of policy focus as part of the Alliance for Cancer Care Equity (ACCE) joint collaboration, including advancing diversity in clinical trials, improving cancer screening and early detection, and increasing access to patient navigation.

Newswise:Video Embedded why-a-targeted-therapy-is-better-than-immunotherapy-for-some-patients-with-inoperable-non-small-cell-lung-cancer
VIDEO
Released: 31-Jan-2024 7:05 PM EST
Why a Targeted Therapy Is Better Than Immunotherapy For Some Patients With Inoperable Non-Small Cell Lung Cancer
Yale Cancer Center/Smilow Cancer Hospital

Non-small cell lung cancer (NSCLC), with an epidermal growth factor receptor (EGFR) mutation, tends not to respond well to immunotherapy treatments, including durvalumab. However, Yale Cancer Center (YCC) researchers recently reported in the Journal of Thoracic Oncology that the targeted therapy osimertinib, when administered after chemotherapy and radiation, is associated with significantly improved progression-free survival (living without the cancer worsening).

Newswise: RWJBarnabas Health and Rutgers Cancer Institute of New Jersey First in State offering Novel form of Liver Cancer Treatment
Released: 30-Jan-2024 2:05 PM EST
RWJBarnabas Health and Rutgers Cancer Institute of New Jersey First in State offering Novel form of Liver Cancer Treatment
Rutgers Cancer Institute of New Jersey

Rutgers Cancer Institute of New Jersey, the state's only National Cancer Institute-designated Comprehensive Cancer Center, together with RWJBarnabas Health, has joined a select number of institutions nationwide that offer a specialized chemotherapy delivery system called hepatic artery infusion (HAI) therapy for patients with liver tumors.

Newswise: Rutgers Cancer Institute of New Jersey Unveils Leadership Enhancements for Next Era of Excellence
Released: 30-Jan-2024 1:05 PM EST
Rutgers Cancer Institute of New Jersey Unveils Leadership Enhancements for Next Era of Excellence
Rutgers Cancer Institute of New Jersey

To further support its mission and vision, Rutgers Cancer Institute of New Jersey has modified its leadership structure by elevating two associate director functions to deputy director positions.

Newswise: MD Anderson designated IAEA Collaborating Centre to focus on improving radiation, radiology and nuclear medicine worldwide
Released: 30-Jan-2024 10:05 AM EST
MD Anderson designated IAEA Collaborating Centre to focus on improving radiation, radiology and nuclear medicine worldwide
University of Texas MD Anderson Cancer Center

The University of Texas MD Anderson Cancer Center today announced the signing of an agreement with the International Atomic Energy Agency (IAEA) to become an IAEA Collaborating Centre.

Newswise: Immunologist Lydia Lynch appointed member of Ludwig Princeton
Released: 29-Jan-2024 1:05 PM EST
Immunologist Lydia Lynch appointed member of Ludwig Princeton
Ludwig Cancer Research

It is with great pleasure that we announce the appointment of Lydia Lynch as a full member of the Princeton Branch of the Ludwig Institute for Cancer Research.

Released: 29-Jan-2024 12:05 PM EST
Cancer Prevention Tipsheet: Reducing cancer mortality starts with exercise, nutrition and early detection
Fred Hutchinson Cancer Center

February is Cancer Prevention Month. While cancer can feel inevitable, random or out of our control, there are things we can do to reduce cancer risk, from exercise and nutrition to annual screenings.

Newswise: Subcutaneous Nivolumab as Effective as IV for Renal Cell Carcinoma — With Much Faster Treatment Time
26-Jan-2024 1:05 PM EST
Subcutaneous Nivolumab as Effective as IV for Renal Cell Carcinoma — With Much Faster Treatment Time
Roswell Park Comprehensive Cancer Center

Subcutaneous injection of the immunotherapy nivolumab (brand name Opdivo) is noninferior to intravenous delivery and dramatically reduces treatment time in patients with renal cell carcinoma, as seen in the results of a large phase 3 clinical trial reported today at the 2024 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium in San Francisco, California.

Released: 25-Jan-2024 12:05 PM EST
Study finds significant disparities in diagnosis and treatment of dementia
UC Davis Health

A new study from UC Davis Health and Oregon Health & Science University reveals significant disparities in dementia care.

Released: 25-Jan-2024 12:00 PM EST
MD Anderson Research Highlights for January 25, 2024
University of Texas MD Anderson Cancer Center

The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention.

Newswise: Cervical cancer rates rising in low-income U.S. counties
24-Jan-2024 5:05 PM EST
Cervical cancer rates rising in low-income U.S. counties
University of Texas MD Anderson Cancer Center

Women in low-income areas of the U.S. face a stark rise in cervical cancer incidence and mortality, according to a new study led by researchers from The University of Texas MD Anderson Cancer Center.

Newswise: Experts Address the Latest on Cervical Cancer Treatment
Released: 25-Jan-2024 9:30 AM EST
Experts Address the Latest on Cervical Cancer Treatment
Rutgers Cancer Institute of New Jersey

Eugenia Girda, MD, FACOG, gynecologic oncologist in the Gynecologic Oncology Program at Rutgers Cancer Institute of New Jersey and RWJBarnabas Health is lead author of a recent clinical practice statement exploring therapies for cervical cancer.

Newswise:Video Embedded novel-immunotherapy-selectively-targets-malignant-t-cells
VIDEO
Released: 24-Jan-2024 3:05 PM EST
Novel Immunotherapy Selectively Targets Malignant T Cells
Yale Cancer Center/Smilow Cancer Hospital

One major hurdle in the development of safe and effective immunotherapies has been the risk of depleting healthy T cells during CAR-T treatment that seeks out and kills cancerous T-cells. In a new study published in Nature Communications, Yale Cancer Center researchers have developed a novel CAR-T cell therapy designed to efficiently kill cancerous T cells while leaving most healthy cells intact.

Released: 24-Jan-2024 3:00 PM EST
MD Anderson to host 2024 Cancer Neuroscience Symposium
University of Texas MD Anderson Cancer Center

The University of Texas MD Anderson Cancer Center will host the 2024 Cancer Neuroscience Symposium, Feb. 28 - Mar. 1, in collaboration the journal Advanced Biology.

   
23-Jan-2024 5:05 PM EST
Exposure to flame retardants linked to premature birth, higher birth weight
UC Davis Health

Exposure to organophosphate ester flame retardants during pregnancy is linked to premature births, according to new research published in Environmental Health Perspectives.

Newswise: New Survey of U.S. Oncologists Reveals Where More Work Can Be Done to Research Treatments for Advanced Non-Small Cell Lung Cancer
Released: 24-Jan-2024 8:50 AM EST
New Survey of U.S. Oncologists Reveals Where More Work Can Be Done to Research Treatments for Advanced Non-Small Cell Lung Cancer
Cancer Research Institute

CRI helped commission a poll of oncologists who say that much more research is required to holistically tackle non-small cell lung cancer.



close
1.76592